| 0.5457 -0.005 (-0.93%) | 12-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.8  |
1-year : | 0.94 |
| Resists | First : | 0.68 |
Second : | 0.81 |
| Pivot price | 0.61 |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.63 |
| MA(100) : | 1.96 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 26 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 9.5 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CUPR ] has closed above bottom band by 18.3%. Bollinger Bands are 91.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.55 - 0.56 | 0.56 - 0.56 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.54 - 0.55 | 0.55 - 0.55 |
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.
Tue, 09 Dec 2025
Cuprina Holdings (Cayman) Limited Announces Financial - GlobeNewswire
Tue, 06 May 2025
Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering - The Manila Times
Fri, 11 Apr 2025
Cuprina Holdings closes $12 million IPO for wound care expansion - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 7.37e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 113 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.81e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 642.9 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 30330 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 68330 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|